# of Displayed Technologies: 16 / 16

Applied Category Filter (Click To Remove): Other


Categories

Enhancing Antibody Therapies Using a NOD2 Agonist
TS-065320 — Stimulating monocytes with a NOD2 agonist increases effectiveness of monoclonal antibody therapy.
An estimated 20,160 new cases of chronic lymphocytic leukemia (CLL) and 4,410 deaths were expected in 2022. Current therapies for CLL include the administration of a monoclonal antibody, such as rituximab, an anti-CD20 antibody, to promote clearance of malignant B cells. The Need Current therapies…
  • College: College of Medicine (COM)
  • Inventors: Tridandapani, Susheela; Butchar, Jonathan; Mehta, Payal; Merchand Reyes, Giovanna; Santhanam, Ramasamy
  • Licensing Officer: Schultz, Teri

CDP-choline a host-directed therapeutic for disease caused by SARS CoV-2 infection.
TS-064192 — The Need: The global impact of the SARS CoV-2 coronavirus has created an urgent need for innovative medical interventions to address the challenges posed by COVID-19. Despite the availability of vaccines, sub-optimal vaccine uptake and concerns about new virus variants necessitate additional medical…
  • College: College of Veterinary Medicine
  • Inventors: Davis, Ian; Schelhorn, Jean
  • Licensing Officer: Dahlman, Jason "Jay"

Transducin β-like protein 1 X-Linked Selective Degraders as Anti-cancer Therapeutics
TS-062685 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers. The Need Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…
  • College: College of Pharmacy
  • Inventors: Cheng, Xiaolin; Alinari, Lapo; Li, Pui-Kai "Tom"; Yang, Rui
  • Licensing Officer: Taysavang, Panya

Underwater Zooplankton Enhancing Light Array (UZELA); A Novel Device for Stimulating Nutritional Therapy in Corals
TS-062571 — The Need Coral reefs are declining at an alarming rate. When temperatures increase by as little as 1-2 °C above their normal thermal maximum for as little as ten days, corals become stressed, lose their endosymbiotic algae, and turn white – hence the term bleaching. When bleached, corals…
  • College: College of Arts & Sciences
  • Inventors: Grottoli, Andrea; Dixon, Shannon; Hulver, Ann Marie; Jackson, Eric; Shea, Ryan; Steck, James
  • Licensing Officer: Willson, Christopher

Modulation of Mismatch Repair and Genomic Stability by miR-155
TS-062322 — The Need The field of molecular biology faces a critical commercial need in the effective diagnosis, treatment, and prevention of cancer-related disorders associated with mismatch repair (MMR) dysfunction. Diseases such as Lynch Syndrome (LS) and hereditary non-polyposis colorectal cancer (HNPCC), …
  • College: College of Medicine (COM)
  • Inventors: Croce, Carlo; Valeri, Nicola
  • Licensing Officer: Willson, Christopher

Diagnosis of Chemoresistant Ovarian Cancer.
TS-062306 — The Need Ovarian cancer is a significant health concern, being the leading cause of gynecological cancer-related deaths in the developed world. Current treatments, such as platinum-based chemotherapy, have limited success due to issues like late-stage diagnosis and chemoresistance. Identifying mole…
  • College: College of Medicine (COM)
  • Inventors: Croce, Carlo; Vecchione, Andrea
  • Licensing Officer: Willson, Christopher

Microrna-21, Mismatch Repair, and Colorectal Cancer
TS-062305 — The Need: Colorectal cancer (CRC) is a significant health concern, with a high incidence rate and limited treatment options, particularly regarding resistance to standard chemotherapy like 5-fluorouracil (5-FU). The management of CRC patients is complicated by the frequent occurrence of primary or a…
  • College: College of Medicine (COM)
  • Inventors: Croce, Carlo; Valeri, Nicola
  • Licensing Officer: Willson, Christopher

Advancing Cancer-Related Technology for Better Prognosis and Treatment
TS-062303 — The Need: Cancer continues to be a significant global health challenge, with conditions like non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) often diagnosed at advanced stages, resulting in poor prognoses. Existing treatment methods, such as TRAIL-based therapy, face obstacle…
  • College: College of Medicine (COM)
  • Inventors: Croce, Carlo
  • Licensing Officer: Willson, Christopher

MicroRNA signatures in human ovarian cancer
TS-062298 — The Need: Ovarian cancer remains a significant challenge in the field of medicine, with late-stage diagnosis and limited effective treatments contributing to high mortality rates. The need for improved diagnostic tools and targeted therapies is evident to address this aggressive disease. Convention…
  • College: College of Medicine (COM)
  • Inventors: Croce, Carlo
  • Licensing Officer: Willson, Christopher

Composition and Methods for Lung Cancer Diagnosis and Treatment
TS-062296 — The Need: Advancing Lung Cancer Detection and Treatment Lung cancer continues to be a global health concern, accounting for the highest number of cancer-related deaths worldwide. In the United States, it is the leading cause of cancer mortality for both men and women, with a disheartening five-year…
  • College: College of Medicine (COM)
  • Inventors: Croce, Carlo; Calin, George
  • Licensing Officer: Willson, Christopher

Composition and Methods for Breast Cancer Diagnosis and Treatment
TS-062295 — The Need: Breast cancer continues to be a significant health challenge, affecting a large number of women worldwide and remaining the second leading cause of cancer-related deaths among women in the United States. Despite advancements in detection and treatment, there is no universally successful m…
  • College: College of Medicine (COM)
  • Inventors: Croce, Carlo; Calin, George
  • Licensing Officer: Willson, Christopher

Albumin-SN-38 Conjugate (AlbuCure) for Cancer Therapy
TS-057776 — A novel protein-drug conjugate of human serum albumin chemically conjugated to SN-38, solubilizing the potent chemotherapeutic. This therapy has the potential to treat many tumors with poor prognosis, including pancreatic, lung, breast, colorectal, ovarian, sarcoma, head and neck cancer, urothelial malignancies, and others.
Many solid tumors have poor prognosis despite recent progress in molecularly targeted therapy and immunotherapy. Irinotecan/CPT-11, a chemotherapy on the WHO Essential Medicines List, is approved for use in colorectal cancer, lung cancer, pancreatic cancer, gastric cancer, malignant glioma, and sa…
  • College: College of Medicine (COM)
  • Inventors: Williams, Terence; Lee, Robert
  • Licensing Officer: He, Panqing

Multi-Functional Drug Delivery Nanodevice for Precision Medicine
TS-041485 — A functionalized DNA nanostructure made through a scaffolded DNA origami molecular self-assembly process to deliver clinically significant concentrations of therapeutics.
This novel therapeutic approach leverages structural nanotechnology to create a DNA nanostructure that acts as a customizable delivery vehicle for therapeutic molecules. The technology allows for a highly tunable and customizable multi-functional drug delivery platform that incorporates interchang…
  • College: College of Engineering (COE)
  • Inventors: Castro, Carlos; Byrd, John; Halley, Patrick; Lucas, Christopher
  • Licensing Officer: He, Panqing

Six Degrees-of-Freedom Quality Assurance Phantom for Radiation Therapy Linear Accelerators
TS-037968 — The medical physics group in the Department of Radiation Oncology has devised a 6DoF phantom that is the first of its kind to fully integrate multiple routine QA tests specifically for a six degrees-of-freedom linac table.
6DoF treatment tables allow for 2 additional degrees (pitch and roll) compared to traditional 4DoF (vertical, lateral, longitudinal, and yaw) when correcting for patient setup during image-guidance prior to treatment delivery. These tables allow for more accurate patient treatments and could poten…
  • College: OSU Wexner Medical Center
  • Inventors: Woods, Kyle; Ayan, Ahmet; Gupta, Nilendu; Woollard, Jeffrey
  • Licensing Officer: Schworer, Adam

Development of STAT3 dimerization inhibitors for cancers
TS-037569 — The constant activation of Signal Transducer and Activator of Transcription 3 (STAT3) is frequently detected in many cancer patients with advanced diseases. About 80% of all cancers overexpress STAT3, including solid tumors, lymphoma, and leukemia. Constant activation of STAT3 activities in nonmal…
  • College: College of Pharmacy
  • Inventors: Li, Pui-Kai "Tom"; Li, Chenglong; Lin, Jiayuh
  • Licensing Officer: He, Panqing

LNA Inhibitor Cocktail Therapy for Lupus
TS-037260 — A cocktail of locked nucleic acids inhibits the inflammatory response in a humanized murine model of lupus.
Systemic lupus erythematosus (SLE) is an orphan disease affecting approximately 5 in every 10,000 individuals. Despite its rare prevalence, this lifelong autoimmune disease has few effective targeted therapies. Current treatments are palliative using anti-inflammatory drugs or broad spectrum immun…
  • College: College of Medicine (COM)
  • Inventors: Jarjour, Wael; Valiente, Giancarlo; Young, Nicholas
  • Licensing Officer: He, Panqing

Loading icon